NOviricid (sodium nitrite lozenge) / Nitric Oxide Innovations - LARVOL DELTA

The Efficacy of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patients of African American and Hispanic Origin: A Randomized Clinical Trial. (PubMed, Am J Med) - "This study did not find a benefit of NOL therapy in COVID-19 patients and was terminated for futility. NOL treatment did not reduce mortality, hospitalization, intubation or a reduction in symptoms duration. The study did find the NO lozenges were well tolerated in high risk patients without reported side effects."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease

The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin (clinicaltrials.gov) - P1/2 | N=524 | Terminated | Sponsor: Nitric Oxide Innovations LLC | N=100 ➔ 524 | Recruiting ➔ Terminated; The study stopped due to futility.

Enrollment change • Trial termination • Infectious Disease • Novel Coronavirus Disease

The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: Nitric Oxide Innovations LLC | Trial completion date: Dec 2021 ➔ Dec 2022 | Trial primary completion date: Nov 2021 ➔ Nov 2022

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin (clinicaltrials.gov) - P1/2; N=100; Recruiting; Sponsor: Nitric Oxide Innovations LLC; Trial completion date: Jul 2021 ➔ Dec 2021; Trial primary completion date: Jun 2021 ➔ Nov 2021

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African Americans (clinicaltrials.gov) - P1/2; N=100; Recruiting; Sponsor: Nitric Oxide Innovations LLC; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease